Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Read on today for some exclusive hiring news and a retraction of a high-profile paper on cancer detection.
The need-to-know this morning
- The FDA rejected a HER3 antibody drug conjugate from Daiichi Sankyo and Merck. The two companies, which signed a multibillion-dollar partnership last year, blamed the rejection on manufacturing issues.
- AbbVie and Genmab won accelerated approval for Epkinly, a bispecific antibody; it will compete with CAR-T therapy and a Roche bispecific.
- Verona Pharma won approval for an inhalable COPD drug, now marketed as Ohtuvayre.
CDC advisers opt for go-slow approach with RSV vaccine recommendation
Though the current RSV vaccines on the market (from GSK, Pfizer, and Moderna) are approved for adults 60 and older, a CDC advisory panel yesterday recommended the vaccines for a just a subgroup of that population — people 75 and older and people 60 to 74 years old with a high-risk condition. Those aged 60 to 74 who aren’t at high risk may still get a vaccine if they want to, but insurers are unlikely to cover it for them without the recommendation of the CDC and its advisory panel, the Advisory Committee on Immunization Practices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect